<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01375491</url>
  </required_header>
  <id_info>
    <org_study_id>090395</org_study_id>
    <secondary_id>5M01RR000827</secondary_id>
    <secondary_id>P30DK063491</secondary_id>
    <nct_id>NCT01375491</nct_id>
  </id_info>
  <brief_title>Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans</brief_title>
  <acronym>DOXY</acronym>
  <official_title>Blockade of Receptor Cleavage in Diabetes Mellitus With an MMP Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ruth L. Kirschstein National Research Service Award</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is a heightened state of inflammation in which production of cytokines and matrix
      metalloproteinases (MMPs) result in loss of function of insulin receptors and insulin
      resistance. Doxycycline (DOX) is a potent MMP inhibitor. We hypothesize that DOX will enhance
      insulin sensitivity and decreases inflammation in obese participants with type 2 diabetes
      (DM2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design and Setting: 84 day (D84), double-blind, randomized, placebo (PL)-controlled clinical
      trial conducted in an academic tertiary care center.

      Patients: Non-DM2 Controls (n=15); participants with DM2 receiving PL (n=13) or DOX (n=11).

      Interventions: All participants were evaluated at day 1 (D1); those with DM2 were also
      evaluated at D84 after DOX 100mg twice daily or PL.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MMP activity</measure>
    <time_frame>Day 1 (baseline) and Day 84</time_frame>
    <description>MMP activity is measured using a charge-changing peptide substrate for MMP-2 and MMP-9</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>Day 1 (baseline) and Day 84</time_frame>
    <description>Measure of global inflammation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with DM2 receiving doxycycline 100mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pills prepared identical to doxycycline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>generic doxycycline 100mg twice daily</description>
    <arm_group_label>Doxycycline</arm_group_label>
    <other_name>Vibramycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator to doxycycline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory, medically stable, able to give informed consent, and comply with the
             protocol.

          -  Obesity with BMI &gt;30 kg/m2.

          -  DM2 for less than 10 years.

          -  7.5% &lt; HA1C &lt; 10%

          -  Taking insulin and/or oral medications (biguanide, sulfonlylurea, etc.)

        Exclusion Criteria:

          -  Mental states that would preclude complete understanding of the protocol and
             compliance.

          -  Chronic illness such as renal failure (with creatinine clearance &lt;80 ml/min for
             Specific Aim 2).

          -  Women of child-bearing age because of the potential hazard to the fetus (doxycycline
             may cause permanent discoloration of the teeth and deposition in bone inhibiting
             growth) and because doxycycline may render oral contraceptives less effective.

          -  Nursing mothers.

          -  Allergy to tetracyclines.

          -  Subjects taking the following drugs: penicillin or it's derivatives, anticoagulant
             therapy, antacids containing aluminum, calcium, or magnesium, iron-containing
             preparations, bismuth subsalicylate, barbiturates, carbamazepine, phenytoin or
             methoxyflurane, thiazolidinediones (TZD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen L Herbst, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego Clinical trials Research Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>DeLano FA, Schmid-Sch√∂nbein GW. Proteinase activity and receptor cleavage: mechanism for insulin resistance in the spontaneously hypertensive rat. Hypertension. 2008 Aug;52(2):415-23. doi: 10.1161/HYPERTENSIONAHA.107.104356. Epub 2008 Jul 7.</citation>
    <PMID>18606910</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2011</study_first_submitted>
  <study_first_submitted_qc>June 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2011</study_first_posted>
  <last_update_submitted>May 17, 2013</last_update_submitted>
  <last_update_submitted_qc>May 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Karen L. Herbst</investigator_full_name>
    <investigator_title>Associate Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>doxycycline</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>obesity</keyword>
  <keyword>inflammation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

